MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- IPCA LABORATORIES LIMITED (pharmaceuticals)
- IPCA LABORATORIES LIMITED Financial Data
IPCA Labs Fact Sheet (IPLB)
Know More: Is India's Economic Recovery Sustainable?
Here is the latest financial fact sheet of IPCA Labs. For more details, see the IPCA Labs quarterly results and IPCA Labs share price and chart. For a sector overview, read our pharmaceuticals sector report.
IPCA LABS Price History
| % ch | % | 12.4 |
| No. of shares | m | 126.20 |
| % ch week | % | 13.0 |
| % ch 1-mth | % | 12.0 |
| % ch 12-mth | % | 153.0 |
| 52 week H/L | Rs | 2,268.0/944.6 |
IPCA LABS Financials
| No. of Mths Year Ending |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
12 Mar-19* |
5-Yr Chart Click to enlarge
|
|---|
| IPCA LABS EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 899 | 888 | 643 | 695 | 1,042 | |
| Low | Rs | 591 | 629 | 503 | 400 | 590 | |
| Sales per share (Unadj.) | Rs | 249.2 | 230.3 | 254.5 | 260.2 | 298.6 | |
| Earnings per share (Unadj.) | Rs | 20.1 | 7.6 | 15.4 | 19.0 | 35.0 | |
| Diluted earnings per share | Rs | 20.1 | 7.6 | 15.4 | 19.0 | 35.0 | |
| Cash flow per share (Unadj.) | Rs | 34.4 | 20.6 | 29.1 | 33.1 | 49.4 | |
| Dividends per share (Unadj.) | Rs | 1.00 | 0 | 1.00 | 1.00 | 3.00 | |
| Adj. dividends per share | Rs | 1.00 | 0.00 | 1.00 | 1.00 | 3.00 | |
| Dividend yield (eoy) | % | 0.1 | 0 | 0.2 | 0.2 | 0.4 | |
| Book value per share (Unadj.) | Rs | 174.1 | 179.0 | 194.6 | 213.0 | 247.1 | |
| Adj. book value per share | Rs | 174.1 | 179.0 | 194.6 | 213.0 | 247.4 | |
| Shares outstanding (eoy) | m | 126.20 | 126.20 | 126.20 | 126.20 | 126.35 | |
| Bonus/Rights/Conversions | - | - | - | - | ESOS | ||
| Price / Sales ratio | x | 3.0 | 3.3 | 2.3 | 2.1 | 2.7 | |
| Avg P/E ratio | x | 37.0 | 99.5 | 37.2 | 28.9 | 23.3 | |
| P/CF ratio (eoy) | x | 21.7 | 36.9 | 19.7 | 16.6 | 16.5 | |
| Price / Book Value ratio | x | 4.3 | 4.2 | 2.9 | 2.6 | 3.3 | |
| Dividend payout | % | 5.0 | 0 | 6.5 | 5.3 | 8.6 | |
| Avg Mkt Cap | Rs m | 94,057 | 95,723 | 72,300 | 69,120 | 103,108 | |
| No. of employees | `000 | 13.0 | 13.1 | 13.3 | 13.3 | 13.4 | |
| Total wages/salary | Rs m | 5,651 | 6,256 | 6,960 | 7,359 | 7,874 | |
| Avg. sales/employee | Rs Th | 2,416.4 | 2,213.3 | 2,414.6 | 2,477.4 | 2,807.0 | |
| Avg. wages/employee | Rs Th | 434.3 | 476.4 | 523.2 | 555.2 | 585.8 | |
| Avg. net profit/employee | Rs Th | 195.4 | 73.3 | 146.2 | 180.6 | 329.0 | |
| IPCA LABS INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 31,444 | 29,065 | 32,122 | 32,836 | 37,732 | |
| Other income | Rs m | 327 | 222 | 210 | 418 | 577 | |
| Total revenues | Rs m | 31,771 | 29,287 | 32,332 | 33,254 | 38,309 | |
| Gross profit | Rs m | 5,363 | 2,896 | 4,381 | 4,505 | 6,901 | |
| Depreciation | Rs m | 1,796 | 1,633 | 1,730 | 1,777 | 1,824 | |
| Interest | Rs m | 284 | 319 | 241 | 240 | 189 | |
| Profit before tax | Rs m | 3,611 | 1,166 | 2,621 | 2,905 | 5,465 | |
| Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Prior Period Items | Rs m | -49 | 0 | 0 | 0 | 0 | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Tax | Rs m | 1,019 | 204 | 675 | 511 | 1,042 | |
| Profit after tax | Rs m | 2,542 | 962 | 1,945 | 2,394 | 4,422 | |
| Gross profit margin | % | 17.1 | 10.0 | 13.6 | 13.7 | 18.3 | |
| Effective tax rate | % | 28.2 | 17.5 | 25.8 | 17.6 | 19.1 | |
| Net profit margin | % | 8.1 | 3.3 | 6.1 | 7.3 | 11.7 | |
| IPCA LABS BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 19,348 | 16,219 | 17,418 | 19,455 | 23,778 | |
| Current liabilities | Rs m | 12,517 | 9,700 | 9,559 | 10,076 | 10,975 | |
| Net working cap to sales | % | 21.7 | 22.4 | 24.5 | 28.6 | 33.9 | |
| Current ratio | x | 1.5 | 1.7 | 1.8 | 1.9 | 2.2 | |
| Inventory Days | Days | 107 | 105 | 100 | 98 | 104 | |
| Debtors Days | Days | 73 | 56 | 57 | 67 | 66 | |
| Net fixed assets | Rs m | 20,540 | 21,429 | 20,779 | 20,435 | 20,368 | |
| Share capital | Rs m | 252 | 252 | 252 | 252 | 253 | |
| "Free" reserves | Rs m | 21,564 | 22,578 | 24,300 | 26,633 | 30,971 | |
| Net worth | Rs m | 21,965 | 22,592 | 24,553 | 26,886 | 31,224 | |
| Long term debt | Rs m | 4,987 | 4,843 | 3,517 | 2,340 | 1,409 | |
| Total assets | Rs m | 41,248 | 38,917 | 39,595 | 41,173 | 45,507 | |
| Interest coverage | x | 13.7 | 4.7 | 11.9 | 13.1 | 30.0 | |
| Debt to equity ratio | x | 0.2 | 0.2 | 0.1 | 0.1 | 0 | |
| Sales to assets ratio | x | 0.8 | 0.7 | 0.8 | 0.8 | 0.8 | |
| Return on assets | % | 6.9 | 3.3 | 5.5 | 6.4 | 10.1 | |
| Return on equity | % | 11.6 | 4.3 | 7.9 | 8.9 | 14.2 | |
| Return on capital | % | 14.3 | 5.4 | 10.2 | 10.8 | 17.3 | |
| Exports to sales | % | 52.9 | 49.2 | 48.6 | 47.6 | 45.9 | |
| Imports to sales | % | 16.7 | 15.3 | 14.2 | 14.9 | 16.6 | |
| Exports (fob) | Rs m | 16,624 | 14,299 | 15,617 | 15,642 | 17,308 | |
| Imports (cif) | Rs m | 5,247 | 4,445 | 4,571 | 4,884 | 6,266 | |
| Fx inflow | Rs m | 16,749 | 14,299 | 15,617 | 15,642 | 17,308 | |
| Fx outflow | Rs m | 6,956 | 5,822 | 4,571 | 4,884 | 6,266 | |
| Net fx | Rs m | 9,793 | 8,477 | 11,046 | 10,759 | 11,042 | |
| IPCA LABS CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | 4,682 | 7,087 | 2,819 | 3,411 | 4,923 | |
| From Investments | Rs m | -6,893 | -2,183 | -1,488 | -1,354 | -1,563 | |
| From Financial Activity | Rs m | 2,505 | -4,615 | -1,591 | -1,304 | -1,832 | |
| Net Cashflow | Rs m | 294 | 288 | -260 | 753 | 1,528 | |
Share Holding
|
Company Information
|
|||||||||||||||||||||||||||||||||||||||||
| CHM: Premchand Godha (MD) | COMP SEC: Harish P. Kamath (VP - Legal) | YEAR OF INC: 1949 | BSE CODE: 524494 | FV (Rs): 2 | DIV YIELD (%): 0.1 |
More Pharmaceuticals Company Fact Sheets: FULFORD INDIA DR. REDDYS LAB ALKEM LABORATORIES LUPIN ELDER PHARMA
Compare IPCA LABS With: FULFORD INDIA DR. REDDYS LAB ALKEM LABORATORIES LUPIN ELDER PHARMA
Compare IPCA LABS With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Today's Market
Sensex Ends 377 Points Higher; Banking and Finance Stocks Rally(Closing)
After opening the day on a flat note, share markets in India extended gains as the session progressed and ended on a strong note, lifted by gains in financials and FMCG stocks.
Views on news
IPCA LABS Share Price Up by 12%; BSE HEALTHCARE Index Up 1.5% (Market Updates)
Oct 27, 2020 | Updated on Oct 27, 2020IPCA LABS share price is trading up by 12% and its current market price is Rs 2,394. The BSE HEALTHCARE is up by 1.5%. The top gainers in the BSE HEALTHCARE Index is IPCA LABS (up 11.5%). The top losers are SHILPA MEDICARE and PIRAMAL ENTERPRISES .
THYROCARE TECHNOLOGIES Share Price Up by 5%; BSE HEALTHCARE Index Up 1.5% (Market Updates)
Oct 27, 2020 | Updated on Oct 27, 2020THYROCARE TECHNOLOGIES share price is trading up by 5% and its current market price is Rs 1,195. The BSE HEALTHCARE is up by 1.5%. The top gainers in the BSE HEALTHCARE Index are THYROCARE TECHNOLOGIES (up 5.1%) and IPCA LABS (up 9.6%). The top losers are ERIS LIFESCIENCES LIMITED (down 0.1%) and SUN PHARMA ADV. RES. (down 0.1%).
IPCA LABS Share Price Up by 7%; BSE HEALTHCARE Index Up 0.1% (Market Updates)
Oct 27, 2020 | Updated on Oct 27, 2020IPCA LABS share price is trading up by 7% and its current market price is Rs 2,272. The BSE HEALTHCARE is up by 0.1%. The top gainers in the BSE HEALTHCARE Index is IPCA LABS (up 6.5%). The top losers are ALEMBIC PHARMA and DR. LAL PATHLABS (down 0.1%).
IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)
Sep 29, 2020 | Updated on Sep 29, 2020For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)
Feb 17, 2020 | Updated on Feb 17, 2020For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
More Views on NewsMost Popular
My View on ITC (Fast Profits Daily)
Oct 23, 2020What do the charts say about ITC?
Why ITC and not HUL is my Idea of a Good Investment Right Now 
(Views On News)
Oct 15, 2020
Rahul Shah discusses HUL's lost decade and its implications for ITC.
Why India's Drone Revolution is a 4x Profit Opportunity (Profit Hunter)
Oct 16, 2020My research on India's leading defence companies brought me to one major player in drone manufacturing.
The Biggest Wealth Creating Opportunity that No One is Talking About (Profit Hunter)
Oct 14, 2020The defence sector has gone under the radar despite positive developments. Here's why this sector can't be ignored for long...
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
TRACK IPCA LABS
- Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON IPCA LABS
IPCA LABS - JUBILANT LIFE SCIENCES COMPARISON
COMPARE IPCA LABS WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.